Safety, effectiveness, and quality of life following pulmonary vein isolation with a multi-electrode radiofrequency balloon catheter in paroxysmal atrial fibrillation: 1-year outcomes from SHINE

Richard Schilling, Gurpreet Singh Dhillon, Claudio Tondo, Stefania Riva, Massimo Grimaldi, Federico Quadrini, Petr Neuzil, Gian-Battista Chierchia, Carlo de Asmundis, Ahmed Abdelaal, Liesbeth Vanderlinden, Tiffany Tan, Wern Yew Ding, Dhiraj Gupta, Vivek Y Reddy, Richard Schilling, Gurpreet Singh Dhillon, Claudio Tondo, Stefania Riva, Massimo Grimaldi, Federico Quadrini, Petr Neuzil, Gian-Battista Chierchia, Carlo de Asmundis, Ahmed Abdelaal, Liesbeth Vanderlinden, Tiffany Tan, Wern Yew Ding, Dhiraj Gupta, Vivek Y Reddy

Abstract

Aims: To evaluate the safety and effectiveness of a compliant multi-electrode radiofrequency balloon catheter (RFB) used with a multi-electrode diagnostic catheter for pulmonary vein isolation (PVI).

Methods and results: This prospective, multicentre, single-arm study was conducted at six European sites and enrolled patients with symptomatic paroxysmal atrial fibrillation. The primary effectiveness endpoint was entrance block in treated pulmonary veins (PVs) after adenosine/isoproterenol challenge. The primary safety endpoint was the occurrence of primary adverse events (PAEs) within 7 days. Cerebral magnetic resonance imaging and neurological assessments were performed pre- and post-ablation in a subset of patients. Atrial arrhythmia recurrence was assessed over 12 months via transtelephonic and Holter monitoring. Quality of life was assessed by the Atrial Fibrillation Effect on Quality of Life (AFEQT) questionnaire. Of 85 patients undergoing ablation per study protocol, PV entrance block was achieved in all (one PV required touch-up with a focal catheter). Acute reconnection of ≥1 PVs after adenosine/isoproterenol challenge was observed in 9.3% (30/324) of PVs ablated. Post-ablation, silent cerebral lesions were detected in 9.7% (3/31) of patients assessed, all of which was resolved at 1-month follow-up. One patient experienced a PAE (retroperitoneal bleed). Freedom from documented symptomatic and all arrhythmia was 72.2% and 65.8% at 12 months. Four patients (4.7%) underwent repeat ablation. Significant improvements in all AFEQT subscale scores were seen at 6 and 12 months.

Conclusion: PVI with the novel RFB demonstrated favourable safety and effectiveness, with low repeat ablation rate and clinically meaningful improvement in quality of life.

Clinicaltrials.gov registration number: NCT03437733.

Keywords: Atrial fibrillation; Electrophysiological mapping; Pulmonary vein isolation; Quality of life; Radiofrequency ablation; Radiofrequency balloon catheter.

© The Author(s) 2021. Published by Oxford University Press on behalf of the European Society of Cardiology.

Figures

Graphical abstract
Graphical abstract
Figure 1
Figure 1
The RFB and circular diagnostic catheter as visualised using the electroanatomical mapping system. The RFB and the circular diagnostic catheter are shown at the ostium of LIPV during ablation, where the bottom panel reflects the RF power being delivered (yellow bar, 0–40 W), temperature measured (orange bar, 0–60 Celsius), starting impedance (dark green, 0–150 Ohms), and current impedance (bright green, 0–150 Ohms) for each of the 10 individual electrodes. The bottom panel also shows the posterior electrodes #1–#3 are turned off. LIPV, left inferior pulmonary vein; LSPV, left superior pulmonary vein; RF, radiofrequency; RFB, radiofrequency balloon catheter; RIPV, right inferior pulmonary vein; RSPV, right superior pulmonary vein.
Figure 2
Figure 2
(A) Voltage map of the left atrium and electrogram recorded by the circular diagnostic catheter (B) before, (C) during, and (D) after LSPV isolation with the RFB. LSPV, left superior pulmonary vein; RFB, radiofrequency balloon; RIPV, right inferior pulmonary vein; RSPV, right superior pulmonary vein.
Figure 3
Figure 3
Kaplan–Meier analysis of 6- and 12-month effectiveness endpoint, time to first documented symptomatic effectiveness failure (per-protocol population, N = 85). AF, atrial fibrillation; AFL, atrial flutter; AT, atrial tachycardia.
Figure 4
Figure 4
AFEQT scores at study baseline and at 3, 6, and 12 months post-ablation (per-protocol population, N = 85). AFEQT, Atrial Fibrillation Effect on Quality-of-life questionnaire. †Satisfaction level—‘How well current treatment controls your atrial fibrillation’. ‡Satisfaction level—‘The extent to which treatment has relieved your symptoms of atrial fibrillation’.

References

    1. Calkins H, Hindricks G, Cappato R, Kim YH, Saad EB, Aguinaga L. et al.; Document Reviewers. HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation. Europace 2018;20:e1–160.
    1. Metzner A, Wissner E, Lin T, Ouyang F, Kuck KH.. Balloon devices for atrial fibrillation therapy. Arrhythm Electrophysiol Rev 2015;4:58–61.
    1. Dhillon GS, Honarbakhsh S, Di Monaco A, Coling AE, Lenka K, Pizzamiglio F. et al. Use of a multi-electrode radiofrequency balloon catheter to achieve pulmonary vein isolation in patients with paroxysmal atrial fibrillation: 12-month outcomes of the RADIANCE study. J Cardiovasc Electrophysiol 2020;31:1259–69.
    1. R Reddy VY, Schilling R, Grimaldi M, Horton R, Natale A, Riva S. et al. Pulmonary vein isolation with a novel multielectrode radiofrequency balloon catheter that allows directionally tailored energy delivery: short-term outcomes from a multicenter first-in-human study (RADIANCE). Circ Arrhythm Electrophysiol 2019;12:e007541.
    1. Holmes DN, Piccini JP, Allen LA, Fonarow GC, Gersh BJ, Kowey PR. et al. Defining clinically important difference in the atrial fibrillation effect on quality-of-life score. Circ Cardiovasc Qual Outcomes 2019;12:e005358.
    1. Packer DL, Kowal RC, Wheelan KR, Irwin JM, Champagne J, Guerra PG. et al. Cryoballoon ablation of pulmonary veins for paroxysmal atrial fibrillation: first results of the North American Arctic Front (STOP AF) pivotal trial. J Am Coll Cardiol 2013;61:1713–23.
    1. Natale A, Reddy VY, Monir G, Wilber DJ, Lindsay BD, McElderry HT. et al. Paroxysmal AF catheter ablation with a contact force sensing catheter: results of the prospective, multicenter SMART-AF trial. J Am Coll Cardiol 2014;64:647–56.
    1. Reddy VY, Dukkipati SR, Neuzil P, Natale A, Albenque JP, Kautzner J. et al. Randomized, controlled trial of the safety and effectiveness of a contact force-sensing irrigated catheter for ablation of paroxysmal atrial fibrillation: results of the TactiCath Contact Force Ablation Catheter Study for Atrial Fibrillation (TOCCASTAR) study. Circulation 2015;132:907–15.
    1. Duytschaever M, De Pooter J, Demolder A, El Haddad M, Phlips T, Strisciuglio T. et al. Long-term impact of catheter ablation on arrhythmia burden in low-risk patients with paroxysmal atrial fibrillation: the CLOSE to CURE study. Heart Rhythm 2020;17:535–43.
    1. Andrade JG, Champagne J, Dubuc M, Deyell MW, Verma A, Macle L. et al.; For the CIRCA-DOSE Study Investigators. Cryoballoon or radiofrequency ablation for atrial fibrillation assessed by continuous monitoring: a randomized clinical trial. Circulation 2019;140:1779–88.
    1. Duytschaever M, Vijgen J, De Potter T, Scherr D, Van Herendael H, Knecht S. et al. Standardized pulmonary vein isolation workflow to enclose veins with contiguous lesions: the multicentre VISTAX trial. Europace 2020;22:1645–52.
    1. Reddy VY, Neuzil P, Koruth JS, Petru J, Funosako M, Cochet H. et al. Pulsed field ablation for pulmonary vein isolation in atrial fibrillation. J Am Coll Cardiol 2019;74:315–26.
    1. Providencia R, Defaye P, Lambiase PD, Pavin D, Cebron JP, Halimi F. et al. Results from a multicentre comparison of cryoballoon vs. radiofrequency ablation for paroxysmal atrial fibrillation: is cryoablation more reproducible? Europace 2017;19:48–57.
    1. Büsing KA, Schulte-Sasse C, Flüchter S, Suselbeck T, Haase KK, Neff W. et al. Cerebral infarction: incidence and risk factors after diagnostic and interventional cardiac catheterization—prospective evaluation at diffusion-weighted MR imaging. Radiology 2005;235:177–83.
    1. Deneke T, Nentwich K, Krug J, Müller P, Grewe PH, Mügge A. et al. Silent cerebral events after atrial fibrillation ablation—overview and current data. J Atr Fibrillation 2014;6:996.
    1. Miyazaki S, Kajiyama T, Yamao K, Hada M, Yamaguchi M, Nakamura H. et al. Silent cerebral events/lesions after second-generation cryoballoon ablation: how can we reduce the risk of silent strokes? Heart Rhythm 2019;16:41–8.
    1. Nakamura K, Sasaki T, Take Y, Okazaki Y, Inoue M, Motoda H. et al. Postablation cerebral embolisms in balloon-based atrial fibrillation ablation with periprocedural direct oral anticoagulants: a comparison between cryoballoon and HotBalloon ablation. J Cardiovasc Electrophysiol 2019;30:39–46.
    1. Lickfett L, Hackenbroch M, Lewalter T, Selbach S, Schwab JO, Yang A. et al. Cerebral diffusion-weighted magnetic resonance imaging: a tool to monitor the thrombogenicity of left atrial catheter ablation. J Cardiovasc Electrophysiol 2006;17:1–7.
    1. Dorian P, Burk C, Mullin CM, Bubien R, Godejohn D, Reynolds MR. et al. Interpreting changes in quality of life in atrial fibrillation: how much change is meaningful? Am Heart J 2013;166:381–7.e8.
    1. Dorian P, Jung W, Newman D, Paquette M, Wood K, Ayers GM. et al. The impairment of health-related quality of life in patients with intermittent atrial fibrillation: implications for the assessment of investigational therapy. J Am Coll Cardiol 2000;36:1303–9.

Source: PubMed

Sponsorer og samarbeidspartnere

Medisinsk tilstand

Legemiddelintervensjoner

3
Abonnere